Stem Cell Regenerative Articles & Analysis
33 news found
Today, scientists are amassing a new arsenal of magic bullets, and new companies are proliferating to carry them forward in the war against cancer and a host of other diseases and disorders. Advances in cell replacement therapy, for example, are making it possible for scientists to genetically engineer a patient’s own T-cells so they can specifically ...
Additionally, the designation validates our belief in the potential of our stem cell regenerative PEDF-Derived Short Peptide (PDSP), which underpins several products in our pipeline, and has the potential to be effective in multiple therapy areas and ...
BRM421 is a first-in-class, innovative drug based on a neurotrophic stem cell regenerative peptide (PDSP). It stimulates stem cell differentiation, repairs the cornea, inhibits inflammation, and promotes recovery in DED. ...
To systematically uncover the therapeutic links between secreted proteins and diseases, Juvena has developed a computational platform that mines proteins secreted by regenerative stem cells and screens this rich pool of drug candidates across therapeutic areas to discover and engineer novel biologics. ...
” BRM421 is a novel, first-in-class regenerative peptide therapy which, if successful, could offer patients full relief of symptoms plus repair the damage to the cornea. BRM421 is derived from BRIM’s proprietary, stem cell regenerative PEDF-derived Short Peptides (PDSPs), which can also be applied across multiple ...
BRM421 is a novel, first-in-class regenerative peptide therapy which, if successful, could offer patients complete relief from dry eye symptoms by stimulating the proliferation and differentiation of stem cells to repair damage to the cornea. BRM421 was developed using BRIM’s proprietary stem cell ...
Senti Bio’s oncology pipeline is primarily focused on three preclinical-stage programs: SENTI-202, a Logic Gated (OR+NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells while sparing the healthy bone marrow; SENTI-301, a regulatable Multi-Armed off-the-shelf CAR-NK cell therapy designed ...
BRM421 is based on BRIM’s proprietary stem cell regenerative Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) technology platform, which underpins several products in its pipeline and has the potential to be effective in multiple therapy areas and indications. The functional domain of PEDF chosen to generate PDSPs can ...
("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 7,555,556 shares of common stock (or common stock ...
TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the launch of The Stem Cell SpaceShot Grant, a $100,000 research funding in the field of stem ...
Sewall Professor, Stanford University School of Medicine, Department of Otolaryngology – Head & Neck Surgery and Institute for Stem Cell Biology and Regenerative Medicine ISCBRM. “We are excited to announce this new, internally-developed initiative for Lineage, and to do it so quickly following the partnership we announced with ...
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions has appointed Mark Borman as Chairman of the Board as Dr. ...
Tiago Fleming Outeiro, PhD received his PhD in Molecular and Cell Biology at the Whitehead Institute for Biomedical Research, MIT, and the University of Chicago. ...
Vancouver, BC, Canada - November 30, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, is pleased to announce a research agreement with the University Health Network (UHN). Through this collaboration, Aspect Biosystems will combine its bioprinting technology with UHN’s protocols for ...
As one of the first results of the collaboration initiated in early 2020 between the Cell Culture and Therapy Laboratory (« LCTC ») of the AP-HM and the Poietis company, this installation is a major milestone in the roadmap to start the first clinical trial of a 3D bioprinted human tissue, which will be a skin substitute bioprinted from patients’ ...
ByPoietis
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of the first comprehensive analysis providing significant support for the existence of naturally pluripotent stem cells in all organs. Pluripotent stem cells have the ability to become any ...
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions will take steps to relaunch its veterinary division to tackle animal health innovation. U.S. Stem Cell’s longstanding ...
SUNRISE, FL – Feb 23, 2021 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce the efforts of NorthStar Biotech Group and USRM Board Members to reinvest in U.S. Stem Cell, Inc. On May 9, ...
SUNRISE, FL – Jan 19, 2021 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce that oral arguments in the case United States v. U.S. Stem Cell Clinic, LLC, et al., took place on January 13, ...
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce that oral arguments for the company’s court case USA v. U.S. Stem Cell Clinic, et al has been set for the docket beginning January 11, 2021. ...